Valuation: ADMA Biologics, Inc.

Capitalization 3.75B 3.63B 3.43B 3.02B 5.37B 326B 5.99B 40.97B 15.12B 136B 14.07B 13.79B 581B P/E ratio 2024 *
30.8x
P/E ratio 2025 * 23.2x
Enterprise value 3.75B 3.63B 3.43B 3.02B 5.37B 326B 5.99B 40.97B 15.12B 136B 14.07B 13.79B 581B EV / Sales 2024 *
8.89x
EV / Sales 2025 * 7.81x
Free-Float
96.15%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-2.61%
1 week-7.77%
Current month-3.65%
1 month-5.64%
3 months-28.56%
6 months-5.41%
Current year-9.27%
More quotes
1 week
15.40
Extreme 15.4
17.06
1 month
15.40
Extreme 15.4
18.20
Current year
15.40
Extreme 15.4
19.25
1 year
5.02
Extreme 5.02
23.64
3 years
1.38
Extreme 1.38
23.64
5 years
1.01
Extreme 1.01
23.64
10 years
1.01
Extreme 1.01
23.64
More quotes
Director TitleAgeSince
Chief Executive Officer 48 2011-09-30
Director of Finance/CFO 52 2024-07-23
Compliance Officer 38 2017-12-31
Manager TitleAgeSince
Director/Board Member 77 2006-12-31
Chairman 61 2012-03-29
Director/Board Member 48 2006-12-31
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
-2.61%-7.77%+184.98%+854.60% 3.75B
-0.26%-6.31%-15.97%+3.13% 78.34B
-1.45%+15.70%+41.96%+53.45% 57.55B
+0.50%+1.85%+101.43%+124.10% 37.18B
-5.44%-8.36%-45.51%-37.71% 20.31B
-0.13%+0.94%+391.54%+837.89% 13.87B
+0.22%+0.63%+75.76%+141.19% 13.55B
+2.77%-9.27%+18.05%+3.42% 12.84B
+1.51%+0.69%-26.71%-28.20% 12.11B
-0.68%-3.50%+4.70%-37.09% 11.45B
Average -0.55%-1.76%+73.02%+191.48% 26.1B
Weighted average by Cap. -0.60%-0.92%+42.63%+88.88%
See all sector performances

Financials

2024 *2025 *
Net sales 422M 408M 386M 340M 605M 36.72B 675M 4.61B 1.7B 15.26B 1.58B 1.55B 65.39B 481M 464M 439M 387M 688M 41.76B 767M 5.24B 1.94B 17.35B 1.8B 1.77B 74.37B
Net income 122M 118M 112M 98.44M 175M 10.62B 195M 1.33B 492M 4.41B 458M 449M 18.91B 169M 163M 155M 136M 242M 14.71B 270M 1.85B 682M 6.11B 635M 622M 26.2B
Net Debt - -
More financial data * Estimated data
Logo ADMA Biologics, Inc.
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Employees
624
More about the company
Date Price Change Volume
25-02-12 15.56 $ -2.02% 1,024,320
25-02-11 15.88 $ -4.68% 1,777,556
25-02-10 16.66 $ -0.30% 1,548,264
25-02-07 16.71 $ -1.24% 1,743,053
25-02-06 16.92 $ +0.30% 2,017,586

Delayed Quote Nasdaq, February 12, 2025 at 01:02 pm EST

More quotes
Trading Rating
Investor Rating
ESG MSCI
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
15.88USD
Average target price
24.27USD
Spread / Average Target
+52.85%
Consensus

Quarterly revenue - Rate of surprise